GlassScriptPhysician profile
David Michael Kopel
NPI 1821529686
$5,132.80
in general payments reported to CMS, 2019-2025
43 companies · $1,185 in 2025
The $1,185 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,051 · 2023: $1,382 · 2024: $1,514 · 2025: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,081.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,022.47 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $438.54 | 2022 | |
| Ucb, INC. | $251.66 | 2023-2025 | Briviact, Fintepla, Rystiggo |
| Alexion Pharmaceuticals, INC. | $222.54 | 2022-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $213.48 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $205.21 | 2022-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $200.23 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $181.53 | 2023-2025 | |
| Lundbeck LLC | $177.25 | 2023-2025 | Vyepti, Rexulti |
| Tg Therapeutics, INC. | $165.93 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $164.94 | 2022-2025 | Ingrezza, Ongentys |
| Argenx US, INC. | $159.47 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Impel Pharmaceuticals INC. | $150.48 | 2022-2023 | Trudhesa |
| Biogen, INC. | $134.80 | 2022-2024 | Vumerity, Tysabri, Skyclarys |
| Otsuka America Pharmaceutical, INC. | $130.06 | 2023-2025 | Rexulti |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $112.07 | 2023-2025 | |
| Genentech USA, INC. | $95.19 | 2022-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Amgen INC. | $90.50 | 2022-2025 | Uplizna |
| Lilly USA, LLC | $73.45 | 2023-2025 | Kisunla, Amyvid, Reyvow |
| Emd Serono, INC. | $71.17 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $70.42 | 2022-2024 | Ongentys 50mg Capsules 30, Crexont |
| Takeda Pharmaceuticals U.S.A., INC. | $67.83 | 2024-2025 | Hyqvia |
| Merz Pharmaceuticals, LLC | $66.06 | 2023-2025 | Xeomin, Inbrija |
| Impel Pharmaceuticals LLC | $61.34 | 2025 | Trudhesa |
| Neurelis, INC. | $59.92 | 2022-2023 | Valtoco |
| Sk Life Science, INC. | $53.92 | 2023 | |
| Collegium Pharmaceutical, INC. | $51.53 | 2022 | |
| Alnylam Pharmaceuticals INC. | $44.66 | 2022-2023 | Onpattro |
| Janssen Pharmaceuticals, INC | $43.04 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $42.52 | 2024-2025 | |
| Grifols USA, LLC | $35.29 | 2024-2025 | Gamunex-C |
| Astrazeneca Pharmaceuticals LP | $33.03 | 2023-2025 | Wainua |
| Ani Pharmaceuticals, INC. | $32.54 | 2023 | Purified Cortrophin Gel |
| Amylyx Pharmaceuticals, INC. | $29.42 | 2023 | Relyvrio |
| Acorda Therapeutics, INC | $24.26 | 2023 | Inbrija |
| Jazz Pharmaceuticals INC. | $23.92 | 2024 | |
| Csl Behring | $22.98 | 2023 | Hizentra |
| Kyowa Kirin, INC. | $20.51 | 2024 | Nourianz |
| Mallinckrodt Hospital Products INC. | $19.29 | 2024 | Acthar |
| Hospira, INC. | $18.37 | 2023 | |
| Upsher-Smith Laboratories LLC | $18.06 | 2022 | |
| Cycle Pharmaceuticals INC | $17.35 | 2025 | Tascenso Odt |
| Avanir Pharmaceuticals, INC. | $15.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kopel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.